Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Harvard Business School

Last Updated: January 27, 2023

Details for Patent: 8,263,647

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 8,263,647 protect, and when does it expire?

Patent 8,263,647 protects ADVIL PM and is included in one NDA.

This patent has twelve patent family members in ten countries.

Summary for Patent: 8,263,647
Title:Treatment of sleep disturbances
Abstract: The present invention provides a new composition for treating pain-associated sleep disturbances, especially shortened sleep duration, comprising ibuprofen and diphenhydramine. The composition is further prepared as a bilayer tablet or caplet, or alternatively as a soft gelatin capsule composition, to prevent interaction between the active ingredients.
Inventor(s): Cook; Graham D. (Midlothian, VA), Koch; Todd S. (Powhatan, VA), Giamalva; David H. (Gleen Allen, VA), Bianco; Justin (Vineland, VA), Fort; James J. (Midlothian, VA), Doyle; Geraldine (Chatham, NJ), Cooper; Steven (Denville, NJ)
Assignee: Wyeth LLC (Madison, NJ)
Application Number:12/082,342
Patent Claim Types:
see list of patent claims
Compound; Dosage form; Composition; Use;

Drugs Protected by US Patent 8,263,647

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Glaxosmithkline ADVIL PM diphenhydramine citrate; ibuprofen TABLET;ORAL 021394-001 Dec 21, 2005 OTC Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,263,647

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 309797 See Plans and Pricing
Canada 2434484 See Plans and Pricing
Germany 60207383 See Plans and Pricing
Denmark 1363608 See Plans and Pricing
European Patent Office 1363608 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.